Promising therapeutic approaches such as blockade of IL-6 trans signaling via sGP130Fc may have the potential for combinatory therapies with similar pharmacological perspectives against the leptin receptor to ultimately reduce deaths from HCC. Here, IL6 is linked to hepatocellular carcinoma.